Vor Biopharma (VOR) Competitors

Vor Biopharma (NYSE:VOR) and Contineum Therapeutics (NASDAQ:CTNM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment, community ranking and earnings.

Do insiders and institutionals hold more shares of VOR or CTNM?

97.3% of Vor Biopharma shares are held by institutional investors. 2.9% of Vor Biopharma shares are held by insiders. Comparatively, 11.3% of Contineum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Do analysts recommend VOR or CTNM?

Vor Biopharma currently has a consensus price target of $7.06, indicating a potential upside of 3,168.71%. Contineum Therapeutics has a consensus price target of $22.50, indicating a potential upside of 382.83%. Given Vor Biopharma's higher possible upside, analysts plainly believe Vor Biopharma is more favorable than Contineum Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	0 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.40
Contineum Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20

Does the MarketBeat Community prefer VOR or CTNM?

Vor Biopharma received 43 more outperform votes than Contineum Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Contineum Therapeutics an outperform vote while only 65.88% of users gave Vor Biopharma an outperform vote.

Company	Underperform	Outperform
Vor Biopharma	Outperform Votes 56 65.88%	Underperform Votes 29 34.12%
Contineum Therapeutics	Outperform Votes 13 100.00%	Underperform Votes No Votes

Which has preferable valuation and earnings, VOR or CTNM?

Contineum Therapeutics has higher revenue and earnings than Vor Biopharma. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Vor Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	-$1.51	-0.14
Contineum Therapeutics	$50M	2.41	$22.72M	-$1.97	-2.37

Is VOR or CTNM more profitable?

Vor Biopharma's return on equity of 0.00% beat Contineum Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Contineum Therapeutics	N/A	-49.92%	-20.52%

Does the media favor VOR or CTNM?

In the previous week, Vor Biopharma and Vor Biopharma both had 1 articles in the media. Contineum Therapeutics' average media sentiment score of 1.89 beat Vor Biopharma's score of -1.00 indicating that Contineum Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Vor Biopharma	Negative
Contineum Therapeutics	Very Positive

Which has more volatility and risk, VOR or CTNM?

Vor Biopharma has a beta of -0.51, suggesting that its stock price is 151% less volatile than the S&P 500. Comparatively, Contineum Therapeutics has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500.

Summary

Vor Biopharma and Contineum Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.